Would you offer adjuvant olaparib to a male patient with HR+, HER2- T2N0 breast cancer with a BRCA2 germline mutation following mastectomy who is not a candidate for adjuvant chemotherapy?
Answer from: Medical Oncologist at Community Practice
Will offer brief thoughts but welcome others as well. First, I think it would be helpful to know what risk stratification has been done to decide the patient should be offered chemotherapy and not just endocrine therapy. Also, it would be useful to know why they are not a candidate for chemotherapy ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
BRCA2 mutations are the most common familial genetic alteration in men with breast cancer and this is not an entirely unusual scenario. The first question I would ask here is, how it was decided that this patient needs adjuvant chemotherapy? In a man with breast cancer, Oncotype recurrence scor...
Comments
Medical Oncologist at Kaiser Permanente Washington
Thanks for your input. This is an elderly patient ...
Thanks for your input. This is an elderly patient ...
Medical Oncologist at Private Practice and Digital Health
With significant comorbidities and competing risks...
With significant comorbidities and competing risks...